Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Alpha-synuclein aggregation / synaptic vesicle: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Neuronal Subtype-Specific Alpha-Synuclein Expression Normali | 0.571 | neurodegeneration | Which cell types show the most significa |
| Microbial Metabolite-Mediated α-Synuclein Disaggregation | 0.511 | neurodegeneration | What are the mechanisms by which gut mic |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 13 hypotheses Top: 0.888
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Long-term perampanel treatment in A53T BAC-SNCA mice with PFF injectio | validation | Lewy body disease | 0.950 | 0.00 | A53T BAC-SNCA transgenic mice | proposed | N/A |
| Longitudinal TLR2 reporter gene study in α-synuclein mice | validation | Parkinson's disease | 0.900 | 0.00 | Thy1.2-α-synuclein transgenic | proposed | N/A |
| PFF uptake in primary hippocampal neurons with inhibitors | exploratory | Lewy body disease | 0.900 | 0.00 | mouse primary hippocampal neur | proposed | N/A |
| Dexamethasone treatment study in α-synuclein mice | validation | Parkinson's disease | 0.850 | 0.00 | Thy1.2-α-synuclein transgenic | proposed | N/A |
| PFF clearance kinetics in Snca knockout mice | validation | Lewy body disease | 0.800 | 0.00 | Snca knockout mice | proposed | N/A |
| TLR expression in α-synuclein overexpressing mice | validation | Parkinson's disease | 0.800 | 0.00 | mice overexpressing human α-sy | proposed | N/A |
| s:** - Dose-response studies showing therapeutic window without toxici | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for P | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiation Mechanis | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Computational Modeling of Alpha-Synuclein Propagation in PD | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Alpha-Synuclein Seed Amplification Assay Validation | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation and Neuro | exploratory | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,070,000 |
| Antiviral Therapy Trial for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Combination Therapy Sequencing in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Alpha-Synuclein Staging and Spreading in DLB — Spatial Propagation Map | validation | Parkinson's Disease | 0.400 | 0.50 | cell_line | proposed | $160,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Meta-analysis of mRNA dysregulation associated with Parkinson's disease and othe [PMID:41183391] | Lin Aung T, Aung YW, Shi X | Biomed Phys Eng Express | 2026 | 1 |
| Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiqui [PMID:30966861] | ["Han X", "Sun S", "Sun Y", "Song Q", "Z | Autophagy | 2020 | 1 |
| A human striatal-midbrain assembloid model of alpha-synuclein propagation. [PMID:40919647] | Tran HD, Shin MK, Yeo XY, Jung S, Junaid | Brain | 2026 | 0 |
| Neuronal titration of Snca via enhancer disruption mitigates disease onset in a [PMID:41496593] | Boyd RJ, Kho AR, McClymont SA, Loftus SK | Brain | 2026 | 0 |
| Perampanel Blocks Transsynaptic α-Synuclein Propagation and Neurodegeneration in [PMID:41508763] | Ueda J, Uemura N, Chang J, Hirato T, Ish | Mov Disord | 2026 | 0 |
| Analysis of α-synuclein seed amplification assay in carriers of GBA1 and LRRK2 p [PMID:41574889] | Fraser KB, Mirelman A, Mabrouk OS, Omer | J Parkinsons Dis | 2026 | 0 |
| Aberrant Protein S-Nitrosylation Mimics the Effect of Rare Genetic Mutations in [PMID:41635116] | Wang Y, Lipton SA | J Neurochem | 2026 | 0 |
| SNCA triplication disrupts proteostasis and extracellular architecture prior to [PMID:41698927] | Statoulla E, Zafeiri M, Chalkiadaki K, V | NPJ Parkinsons Dis | 2026 | 0 |
| Gene therapy targeting synaptopathy linked with Alzheimer's and Parkinson's dise [PMID:41730496] | Panda SP, Saraswat N, Singh V | Neuroscience | 2026 | 0 |
| Degradation of alpha-synuclein/SNCA mRNA by RNautophagy. [PMID:41747943] | Kabuta C, Hakuno F, Kataoka N, Takahashi | Neurochem Int | 2026 | 0 |
| An update on the monogenic causes of Parkinson's disease: Impact on patient stra [PMID:41759745] | Asmi S, Krishnan A, Alexander SM, Mohame | Ageing Res Rev | 2026 | 0 |
| N-acetyl-l-leucine lowers α-synuclein levels and improves synaptic function in P [PMID:41766663] | Song P, Chen C, Franchini R, Duong B, Wa | J Clin Invest | 2026 | 0 |
| Genome editing in Parkinson's disease: Unlocking therapeutic avenues through CRI [PMID:41905621] | ["Singh R", "Maity P", "Jaiswal C"] | Neurochemistry international | 2026 | 0 |
| Utility of Drosophila for studying hypoxia-inducible factor (HIF) in neurodegene [PMID:40976499] | Serebrovska Z, Xi L, Khetsuriani M, Prot | Brain research | 2025 | 0 |
| Revisiting Parkinson's disease definition and classification: insights from two [PMID:40906256] | ["Reyes N", "Pajo A", "Saranza G", "H\u0 | Journal of neural transmission | 2025 | 0 |
| Advancing Parkinson's diagnosis: seed amplification assay for α-synuclein detect [PMID:39760833] | ["Carrazana E", "Montalb\u00e1n-Guti\u00 | Molecular and cellular biochem | 2025 | 0 |
| MEK1/2 inhibitors suppress pathological α-synuclein and neurotoxicity in cell mo [PMID:40367191] | ["Wang H", "Wang Q", "Xu H", "Wu Y", "Ch | Science translational medicine | 2025 | 0 |
| Uncovering injury-specific proteomic signatures and neurodegenerative risks in s [PMID:40545497] | ["Mantash S", "Aboulouard S", "Dakik H", | Signal transduction and target | 2025 | 0 |
| Nucleolin inhibits α-synuclein to attenuate aconitine's neurotoxicity. [PMID:40482618] | ["Liu G", "Zuo W", "Zhang Z", "Lv W", "X | Phytomedicine : international | 2025 | 0 |
| The role of neuroimaging in Parkinson's disease. [PMID:34532856] | Bidesi NSR, Vang Andersen I, Windhorst A | J Neurochem | 2021 | 0 |
Multi-agent debates referencing this entity
Hypotheses and analyses mentioning Alpha-synuclein aggregation / synaptic vesicle in their description or question text
No additional research found